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Ordered and accurate processing of the human immunodeficiency virus type 1 (HIV-1) GagPol polyprotein
precursor by a virally encoded protease is an indispensable step in the appropriate assembly of infectious viral
particles. The HIV-1 protease (PR) is a 99-amino-acid enzyme that is translated as part of the GagPol
precursor. Previously, we have demonstrated that the initial events in precursor processing are accomplished
by the PR domain within GagPol in cis, before it is released from the polyprotein. Despite the critical role that
ordered processing of the precursor plays in viral replication, the forces that define the order of cleavage
remain poorly understood. Using an in vitro assay in which the full-length HIV-1 GagPol is processed by the
embedded PR, we examined the effect of PR context (embedded within GagPol versus the mature 99-amino-acid
enzyme) on precursor processing. Our data demonstrate that the PR domain within GagPol is constrained in
its ability to cleave some of the processing sites in the precursor. Further, we find that this constraint is
dependent upon the presence of a proline as the initial amino acid in the embedded PR; substitution of an
alanine at this position produces enhanced cleavage at additional sites when the precursor is processed by the
embedded, but not the mature, PR. Overall, our data support a model in which the selection of processing sites
and the order of precursor processing are defined, at least in part, by the structure of GagPol itself.
The proteins that make up the retroviral core particle are
translated as part of polyprotein precursors (13, 32). Process-
ing of these precursors is accomplished by a viral protease
(PR) that is contained within one of the precursors (9). During
virus assembly, the processing sites within the retroviral pre-
cursor proteins are cleaved by the viral PR (9, 13, 45). Accurate
and precise PR-mediated precursor processing is an absolute
requirement for the production of fully infectious viral parti-
cles; mutations that produce imprecise cleavage at individual
sites or that alter the order in which sites are cleaved result in
the elaboration of aberrantly assembled virions that are mark-
edly less infectious (5, 20, 22, 36, 42, 54, 57).
In the case of the human immunodeficiency virus type 1
(HIV-1), the structural proteins of the core particle are con-
tained within the Gag precursor (Fig. 1) (13). From the amino
terminus, these are the matrix (MA), capsid (CA), nucleocap-
sid (NC), and p6 (17, 18). There is a small spacer peptide, p2,
between CA and NC; an additional spacer peptide, p1, resides
between NC and p6 (17, 18, 36, 51, 56). The 5 end of the pol
precursor reading frame overlaps with gag; Pol is translated as
a fusion protein with Gag (GagPol) as the result of a 1
frameshift, producing a Gag/GagPol ratio of 20:1 (19, 39). Pol
contains several enzymes, including the PR itself as well as the
reverse transcriptase (RT) and integrase (IN) (21, 27, 50).
There is an additional PR cleavage site within RT. Processing
at this site has been estimated to occur in about 50% of the
GagPol molecules and produces a truncated, 51-kDa form of
the 66-kDa full-length RT that is missing the carboxy-terminal
RNase H domain (12, 26, 30, 47, 50, 52).
The PR becomes active only as a homodimer; the enzyme
active-site cleft is comprised of residues from two monomers
(6, 53). Numerous crystal structures of the mature, 99-amino-
acid PR have been described, and several groups have con-
ducted exhaustive genetic and biophysical analyses of the ma-
ture dimer (10, 27, 31, 44, 55). It has been estimated that
approximately 50% of the interactions that maintain the ma-
ture dimer are found in a four-stranded antiparallel -sheet;
the first four residues of each of the protease monomers form
the two outer strands of the -sheet, and the last four residues
(residues 96 to 99) of each monomer form the two inner
strands (53).
The location of the PR within a large precursor combined
with the requirement that the enzyme must dimerize to be-
come active dictates that the PR domains of two GagPol pre-
cursors, along with the precursors themselves, must dimerize.
The first processing events are carried out by the embedded
PR, before it is released from the GagPol precursor. The initial
cleavages in GagPol are intramolecular; the activated PR
dimer on one pair of GagPol molecules cleaves these initial
sites on those same molecules (33).
Several studies have examined the order of cleavage for the
different sites within the HIV-1 Gag precursor, and there is
general agreement that the first cleavage occurs between the
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p2 spacer peptide and the NC protein (11, 15, 23, 28, 35, 36,
54). Intermediate cleavages occur at the MA/CA and p1/p6
sites (36, 54). The relative rate of cleavage at different sites
within the precursors has also been evaluated. Using a system
in which the Gag precursor is processed by the addition of
purified PR in trans, the rates of cleavage were determined to
vary by as much as 400-fold between sites (35, 36). Of note, this
difference is much greater than that reported for the cleavage
of peptides designed to reflect the sequence at the different
sites (3, 7, 23, 29, 38, 40, 48).
Despite the critical role played by the orderly processing of
the Gag and GagPol precursors in virus assembly and replica-
tion, little is known about the factors that determine the order
in which different sites are cleaved. The initial steps in the
processing of the GagPol precursor produced in vitro are in-
tramolecular cleavages that are carried out by the embedded
PR in cis (33). Although it seems likely that the context of the
PR domain within GagPol influences the early events in pre-
cursor processing, the behavior of the PR in cis versus trans has
not been extensively examined. Using an in vitro expression
system in which full-length GagPol is cleaved by its embedded
PR, we sought to define the effect of the context of the PR
(precursor-embedded or mature, free PR) on precursor pro-
cessing. We demonstrate that the embedded PR is constrained
to make a limited number of cleavages by its location within
GagPol. Further, substitutions at the first amino acid in the
PR, a proline, lift this constraint and free the PR domain
within GagPol to cleave additional native processing sites in
the precursor not cleaved by the wild-type (WT) embedded
PR. Our data demonstrate that the context of the PR within
GagPol influences the order of precursor processing and indi-
cate that there are structural determinants within the PR,
outside of the active site, that help regulate the ordered selec-
tion of cleavage sites during precursor processing. Overall,
these findings further our understanding of the regulation of
the initial events in HIV-1 maturation and suggest that the
ordered pattern of precursor cleavage is defined, at least in
part, by the structure of GagPol itself.
MATERIALS AND METHODS
Plasmid construction and mutagenesis. The construction of pGPfs and pGPfs-
PR was previously described (34). Briefly, pGPfs contains the full-length GagPol
open reading frame downstream of the bacteriophage T7 promoter. A contigu-
ous GagPol open reading frame was constructed by site-directed mutagenesis
and exactly produces the major GagPol product (the same amino acid sequence)
found in virions (pr160) (14, 19). The pGPfs-PR plasmid contains an additional
D25A mutation of the catalytic aspartate with the PR domain and thus lacks
intrinsic PR activity. Site-directed mutagenesis was performed as described pre-
viously (1, 24), and mutations were confirmed by chain termination sequencing
(41).
In vitro assays for the proteolytic processing of GagPol. Expression of GagPol
in vitro and cis-processing reactions were performed as previously described (33,
34). Briefly, the GagPol constructs were translated using a coupled transcription/
translation system (TNT system; Promega) in a rabbit reticulocyte lysate (RRL).
The reaction was carried out in 50-l total volume with 20 Ci of [35S]cysteine
(1,000 Ci/mM; Amersham Pharmacia Biotech). trans PR processing reactions
were performed as described previously (33, 34) in 50-l reaction volumes
containing approximately 160 pM GagPol (final concentration) and purified
protease in a buffer previously described (34). Either purified WT or P1A mutant
protease was added to initiate the reactions, and aliquots were removed at
specific times for evaluation by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and densitometry (33). Competitive inhibitions of cis- and trans-
processing reactions by ritonavir, sequinavir, or indinavir were performed as
described previously (33). Reactions containing WT or P1A mutant PR con-
tained equivalent amounts of protease as determined by specific activity on
GagPol substrate.
Expression, titration, and purification of HIV PR. WT and P1A mutant
protease was purified as described previously (16, 34). For peptide studies, the
two protease preparations were titrated to determine the percentage of active
sites determined by inhibition with tight binding inhibitor (46).
Determination of Michaelis-Menten constants. The Michaelis-Menten con-
stants kcat, Km, and kcat/Km and Ki values were determined for each variant as
previously described (4). The chromogenic substrate K-A-R-V-LNph-E-A-
nL-G, which mimics the CA-p2 cleavage site, was used to determine the inhibitor
binding constants of each variant at 37°C in sodium acetate buffer (0.05 M
sodium acetate, 0.15 M NaCl, 0.002 M EDTA, 0.001 M dithiothreitol, pH 4.7).
Cleavage of the substrate was monitored using a Hewlett-Packard 8452A spec-
trophotometer equipped with a seven-cell sample handling system as described
by Dunn et al. (8). The inhibition constants Ki were determined by monitoring
the inhibition of hydrolysis of the chromogenic substrate as described by Bhatt
and Dunn (2). Analysis of the fluorescent substrate R-E(EDANS)-R-K-V-LF-
L-D-G-K(DABCYL)-R was done in the same buffer and temperature using a
CytoFluor Multi-Cell plate reader from PerSeptive Biosystems.
RESULTS
Substitution of the amino-terminal proline in the embedded
PR with alanine relieves the block to PR-mediated cleavage at
the processing site between the RNase H domain of RT and IN.
Expression of full-length WT GagPol in an in vitro RRL tran-
scription/translation system results in PR activation and or-
dered processing of the precursor at two cleavage sites; an
initial cleavage is observed between the NC and p2 proteins,
and a second cleavage occurs at a site within the transframe
region (TF) between amino acids 440 and 441 (34). These
intramolecular processing events produce processing interme-
diates of 120, 113, and 41 kDa, corresponding to the NC-IN,
TF (L441)-IN, and MA-p2 fragments, respectively (Fig. 1 and
2A) (33, 35). Of note, we do not observe additional cleavages
in the precursor despite prolonged incubation (data not
shown). It seems most likely that the lack of additional pro-
cessing events is due to the low concentrations of the GagPol
precursors in the RRL. We have estimated that the concen-
tration of the precursor produced in this system is 1 nM, which
is close to the reported Kd of the mature, full processed PR
(34).
We used this system to examine the processing of GagPol by
the embedded PR. We were particularly interested in charac-
terizing the structural determinants that define the order in
which different GagPol sites are cleaved. Previously, we dem-
onstrated that substitution of the proline at position 1 of the
embedded PR with any one of several amino acids (e.g., Ala,
Gly, Leu, or Phe) results in additional cleavages in the GagPol
precursor (Fig. 2A) (35). The sizes of these additional cleavage
products (67 kDa, 66 kDa, and 62 kDa) were consistent with
enhanced processing at three sites within GagPol: the amino
FIG. 1. Schematic of GagPol expression vector pGPfs. pGPfs con-
tains a contiguous gagpol open reading frame produced by mutagen-
esis. Upon expression, pGPfs produces a full-length GagPol pr160
precursor with the same sequence as the predominant GagPol precur-
sor found in infected cells (14, 20). Construction of pGPfs was previ-
ously described (34).
10602 PETTIT ET AL. J. VIROL.
terminus of the PR, between the RT and RNase H, and be-
tween the RNase H domain of RT and IN. Cleavages at these
sites would produce three additional processing intermediates,
TF-RT (67 kDa), RT-RH (66 kDa), and PR-RT (62 kDa).
We identified the precise locations of these cleavage sites by
introducing blocking mutations at the known RNase H/IN
processing site. Others have noted that substitution of an Ile
for the P1 (N-terminal) amino acid of the scissile bond inhibits
PR-mediated processing for a majority of the HIV-1 process-
ing sites (3, 37, 40, 49). A GagPol construct containing an Ile
blocking mutation at the RNase H/IN processing site and a
Pro-to-Ala substitution at position 1 of the PR was generated
(pGPfs-P1A RH/IN). The 67-, 66-, and 62-kDa fragments ob-
served upon expression of GagPolP1A are not seen in the
presence of the Ile blocking substitution, indicating that they
arise from cleavage at this site. In addition to the abrogated
proteolytic cleavage at the RT-IN junction, inhibition of cleav-
age of the RT/RH site was also noted (Fig. 2A, P1A-RH/IN,
67- and 62-kDa products). These observations are consistent
with the findings of Sluis-Cremer et al. (43), who suggested
that formation of the p66/p66 homodimer via removal of IN is
an obligatory step in the processing pathway to the p66/p51
heterodimer. These data indicate that the P1A substitution
allows the embedded PR to make additional cleavages at na-
tive processing sites that are in the C-terminal portion of the
precursor (Fig. 2B).
Purified mature P1A PR added in trans to GagPol produces
a cleavage pattern that is indistinguishable from the trans-
processing pattern observed with purified mature WT PR. We
reasoned that the altered processing pattern observed with the
embedded PR containing the P1A substitution might be de-
pendent on the context of the mutant PR within GagPol. To
assess the effect of the P1A mutant on the 99-amino-acid
mature PR, we examined the trans processing of a full-length
GagPol substrate containing an inactivating mutation in its PR
domain; the substitution of an alanine for the aspartic acid
present at position 25 (the active site) of the embedded PR
(GagPolPR-) renders the embedded enzyme inactive. For
these experiments, purified WT or P1A PR was provided in
trans to full-length GagPolPR- and processing was monitored
over time.
As noted above (Fig. 2A), the processing of GagPol by the
embedded mutant P1A PR produced a pattern of cleavages
that was markedly different than the processing intermediates
observed with the embedded WT PR. In contrast, the purified
WT and P1A PRs produced identical cleavage patterns when
added to GagPolPR- in trans (Fig. 3). For both the purified
WT and P1A PRs, processing occurred in an order similar to
that seen with the WT embedded PR; cleavage at the p2/NC
site yields 120- and 42-kDa intermediates and is followed by
processing at the site within the precursor (Fig. 3). In partic-
ular, we observed that the generation of the 67-, 66-, and
62-kDa products occurred at similar time points for both WT
and P1A trans protease (Fig. 3).
To determine whether the altered processing pattern seen
with the embedded P1A PR was due to an increase in affinity
of the P1A mutant for the RNase H/IN cleavage site, we
measured the Km of the P1A mutant for a peptide correspond-
ing to this site [R-E(EDANS)-R-K-V-LF-L-D-G-K(DAB-
CYL)-R]. As shown in Table 1, the Km of the purified P1A
mutant PR for this peptide is very similar to that observed with
the WT enzyme and we observed a 3.7-fold decrease in kcat/Km
by P1A compared to WT protease.
The embedded P1A PR, but not the purified mature P1A, is
more sensitive than WT enzyme to inhibition by PR inhibitors.
Previously, we demonstrated that purified mature WT PR
added to full-length GagPolPR- in trans is dramatically more
FIG. 2. Identification of the additional processing intermediates
and products generated by the activated P1A protease in full-length
HIV-1 GagPol. A) WT GagPol or GagPol containing mutations was
expressed in vitro and allowed to autoprocess for the indicated times as
described previously (34). WT GagPol initially cleaves the NC/p2 site,
followed by the TF F440/L441 site to generate 120-kDa NC-IN and
113-kDa TFL441-IN products. P1A protease shows altered site selec-
tion, resulting in enhanced cleavage at the TF/PR, RH/IN, and RT/IN
sites to generate additional 107-, 67-, 66-, and 62-kDa products. P1A-
RH/IN containing P1 Ile substitution of the RH/IN site blocks pro-
cessing of the site and results in the disappearance of the 67-, 66-, and
62-kDa products. The positions of molecular mass markers are shown
on the left. The composition of products is shown abbreviated to their
N and C-terminal domains by accepted nomenclature (25). The mo-
lecular mass designation of products is derived from the published
sequence or from the accepted popular designation. B) Schematic of
GagPol cleavages by the activated protease in vitro. WT GagPol pro-
tease initiates intramolecular processing at the p2/NC site, followed by
the TF F440/L441 site (33). P1A mutation of the protease domain
(P1A) altered site selection with enhanced cleavage of the TF/PR,
RH/IN, and RT/RH sites. A protease P1A mutation in addition to a
blocking mutation at the RH/IN site (P1A-RH/IN) restores restricted
processing of the RH/IN and RT/RH sites.
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sensitive to inhibition by an active-site PR inhibitor (PI) than
the WT embedded PR (33). Specifically, we established that
approximately 10,000-fold more ritonavir is required to inhibit
the embedded PR from processing the precursor than is re-
quired to inhibit purified PR added in trans. This large differ-
ence in sensitivity to inhibition is consistent with our observa-
tion that the initial cleavages by the embedded PR are
intramolecular processing events (33). Given the altered Gag-
Pol processing patterns produced by the embedded, but not
the purified, P1A PR, we determined the sensitivity of the
mutant enzyme to inhibition by several of the available PR
inhibitors, including ritonavir, saquinavir, and indinavir.
Higher concentrations of ritonavir were required to inhibit
the embedded WT PR from cleaving the p2/NC site than was
required to inhibit the P1A PR from cleaving the same site. As
summarized in Table 2, we found that the embedded P1A PR
is also more sensitive than the WT PR to inhibition by indina-
vir for cleavage at the p2/NC site. The increase in sensitivity
ranges from a 4.0-fold decrease in the 50% inhibitory concen-
tration (IC50) for ritonavir to a 6.4-fold decrease for indinavir.
The decrease in IC50 for the P1A protease, while small, was
consistent across multiple experiments. Thus, P1A protease as
a component of GagPol has a modest increase in sensitivity to
ritonavir and indinavir. In contrast, the concentration of pro-
tease inhibitor (PI) required to inhibit either the purified P1A
or WT protease from processing the full-length GagPolPR- in
trans was quite similar (Table 2).
We also determined the Ki for the purified P1A and WT
enzymes in trans for each of the PIs (Table 3). The sensitivities
of the purified P1A PR to inhibition by the three drugs were
similar to those observed with the WT enzyme.
DISCUSSION
The initial steps in retroviral precursor processing and viral
assembly include the interaction of GagPol precursors and PR
activation. Our previous studies have demonstrated that ex-
tra-PR regions in GagPol promote PR activation and dimer-
ization (33). Following the dimerization of the GagPol precur-
sors and their embedded PR domains, the activated enzyme
makes its initial intramolecular cleavages. Therefore, the
dimerization of the PR domains within the two GagPol pre-
cursors, the concomitant activation of the embedded enzyme
homodimer, and the initial processing events are inextricably
linked.
Published crystallographic studies of the mature 99-amino-
acid PR have established that the two monomers interact in
large part through a dimer interface in which the amino-ter-
minal four amino acids (Pro-Gln-Ile-Thr) form the outer
strands and the carboxy-terminal amino acids (Thr-Leu-Asn-
Phe) comprise the inner strands of a four-stranded antiparallel
FIG. 3. Similar site selection and processing kinetics of the GagPol processing sites by the purified WT and P1A proteases. The full-length
GagPol precursor (pr160) was generated by translation in vitro and used as a substrate to evaluate the kinetics of processing by purified WT and
P1A proteases provided in trans. Products were gathered at the indicated time points (in minutes [] or hours) and separated by electrophoresis.
The positions of molecular mass markers are shown on the left. Products are denoted in abbreviated form by their N-terminal and C-terminal
domains according to accepted nomenclature (25).
TABLE 1. Michaelis-Menten constants for the purified WT and
P1A proteases using the RH-IN processing site as a substrate
Protease Km (M) kcat (s) kcat/Km (M/s)
WT 14  2 0.85  0.07 0.06  0.01
P1A 17  2 0.26  0.01 0.016  0.002
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-sheet (53). Despite the extensive structural studies of the
mature PR, very limited information is available regarding the
structure of the embedded PR within GagPol. This, in turn, has
limited our ability to draw definitive conclusions about the
influence of the context of surrounding GagPol sequences on
ordered precursor processing by the embedded PR.
Using a system in which the full-length GagPol precursor is
processed by its embedded PR, we sought to examine the
extent to which the initial precursor processing events are
influenced by the context of the PR within GagPol. Our studies
reveal several new insights into the role that the PR dimer
interface plays in directing the order of GagPol cleavage. First,
these data indicate that the rigid, amino-terminal Pro con-
strains the embedded PR from processing cleavage sites down-
stream of the PR domain in GagPol. A role in defining the
order of precursor processing appears to be limited to this
position; as we have reported previously, substitutions at other
positions in the dimer interface do not alter the pattern of
precursor processing at these downstream sites (34). This con-
clusion is also strengthened by the observation that similar
results are obtained when the amino-terminal Pro is replaced
by Leu, Phe, or Gly (34). Second, we demonstrate that the
context of the PR within GagPol influences the order in which
sites within the precursor are processed; the purified enzyme
containing a P1A substitution did not display the altered pro-
cessing phenotype and did not display an appreciably altered
Km for the RNase H/IN site (Table 1). Finally, the embedded
PR with the P1A substitution was more sensitive to inhibition
by two of the three active-site PR inhibitors than the WT PR.
Of note, the purified P1A PR did not share this enhanced
susceptibility (Table 2).
We were surprised to find that the embedded P1A PR was
more sensitive to inhibition by two of the PR active-site inhib-
itors tested. We believe that this reflects the altered context of
the PR domain embedded within GagPol. As noted above,
relieving the constraints of the rigid Pro at position 1 of the PR
domain allows cleavage of the additional downstream sites.
This is consistent with the interpretation that the PR domain of
the precursor with the P1A substitution is more flexible and
thus able to access these additional sites. It seems likely that
the increased flexibility that allows the embedded PR to cleave
the downstream sites also increases the accessibility of the
enzyme active site. Therefore, the enhanced susceptibility of
the embedded P1A PR may be explained by an increased
accessibility of the enzyme active site to the inhibitor. Alter-
natively, the enhanced susceptibility of the PR with the P1A
substitution may be explained by unanticipated changes in the
enzyme active site. As we do not observe the enhanced sus-
ceptibility in the purified mutant PR, this latter possibility
seems less likely. However, in the absence of structural infor-
mation for the precursor, we cannot definitively distinguish
between these two interpretations.
In summary, these results demonstrate that substitutions
outside of the PR active site influence the selection of process-
ing sites for cleavage. Further, we have identified the initial
amino acid in the GagPol PR domain as playing a critical role
in constraining the order of cleavage in the WT precursor.
Taken together, our data are consistent with a model in which
two factors have evolved that define the ordered processing of
the cleavage sites within the HIV-1 GagPol precursor. First,
the order of cleavage is influenced by the well-described char-
acteristics of the processing sites themselves as reflected in
peptide-based studies (3, 7, 23, 29, 38, 40, 48). Second, our data
also support the notion that structural constraints act on the
PR domain within the context of the GagPol precursor and
that the structure of the precursor helps define the order of the
initial cleavage events.
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